Does Ozempic help gout? What the uric acid research shows

The short answer

GLP-1 drugs like Ozempic and Wegovy are not a gout treatment, and the evidence that they directly lower uric acid is weak and inconsistent. When gout does improve, the benefit most likely comes from the weight loss itself, not from the drug acting on uric acid. For lowering urate, SGLT2 diabetes drugs have far stronger data.

If you have gout and you are starting a GLP-1, or you already take one, you have probably wondered whether it helps your joints or makes flares worse. A June 2025 review in the journal Pharmaceutics looked at exactly this question. The honest picture is less tidy than social media suggests.

What is gout, and where does uric acid fit in?

Gout is the most common form of inflammatory arthritis, affecting roughly 5.1% of US adults. It happens when uric acid builds up in the blood, forms sharp crystals, and those crystals settle in a joint. The result is the sudden, searing pain of a gout flare, often in the big toe.

Hyperuricemia means a serum urate level above about 6.8 mg/dL, the point where uric acid starts to crystallise. Type 2 diabetes and gout travel together, because both are tied to higher body weight, high blood pressure and kidney strain. That overlap is why researchers started asking whether the newer diabetes and weight-loss drugs might help gout too.

Do GLP-1 drugs actually lower uric acid?

This is where the hype runs ahead of the data. The review is blunt about it: the effect of GLP-1 drugs on uric acid levels and uric acid excretion in humans is unclear. Across the studies, the results point in different directions depending on the drug and the trial.

Drug	Effect on uric acid	Evidence so far
Semaglutide (Ozempic, Wegovy)	Mixed - some drop, some no change	Small retrospective studies
Liraglutide (Victoza, Saxenda)	Mixed - often no change	Several small studies
Exenatide (Byetta)	No clear change	Small trials
Dulaglutide (Trulicity)	Mostly no change	Small studies
Tirzepatide (Mounjaro, Zepbound)	No published data	None
Mazdutide (investigational)	Consistently lower	Early trials, mostly in China

Take semaglutide, the drug in Ozempic and Wegovy. In one retrospective study of 43 adults with obesity, 24 weeks of semaglutide lowered serum urate from about 6.7 to 5.8 mg/dL (p<0.01). That looks encouraging. But in a separate trial that compared semaglutide head to head with the SGLT2 drug empagliflozin, semaglutide did not lower uric acid at all, while empagliflozin did (p<0.05).

Liraglutide tells a similar story. In the LOSE-IT trial, an initial diet lowered urate by 0.21 mg/dL, and adding liraglutide dropped it a further 0.48 mg/dL versus 0.07 mg/dL on placebo. Yet in a 36-month comparison, liraglutide lowered urate by 0.5 mg/dL while SGLT2 drugs lowered it by 0.8 mg/dL, and the SGLT2 group ended up significantly lower. Several other liraglutide studies found no change at all.

Two points stand out. Tirzepatide, the drug in Mounjaro and Zepbound, has essentially no published gout or uric acid data, because its trials focused on weight, blood sugar, heart and kidney outcomes. And the one GLP-1-type drug that did lower urate reliably, mazdutide, is still investigational. In a phase 2 trial of 248 adults, mazdutide lowered uric acid by up to roughly 1.8 mg/dL over 24 weeks (p<0.0001), but it is not approved and the trials were mostly in China.

The mechanism nobody has pinned down

Researchers have a theory for how a GLP-1 drug might lower uric acid. It may block a kidney transporter called NHE3, which would make the kidney flush out more uric acid. The problem is that a rat study found the opposite effect, so the idea is unproven. In plain terms: nobody has shown a clear, direct way that these drugs lower urate in people. The most believable route is simply the weight loss.

How GLP-1 drugs compare with SGLT2 inhibitors for gout

If your real goal is lowering uric acid, this comparison matters. SGLT2 inhibitors are a different class of diabetes drug (empagliflozin, dapagliflozin, canagliflozin), and the gout evidence for them is much stronger than for GLP-1 drugs.

• In a Danish study of 11,047 people, starting an SGLT2 inhibitor was linked to a lower rate of new gout (4.7 per 1,000 person-years) than starting a GLP-1 drug (7.0 per 1,000 person-years).
• In a far larger analysis of 295,907 adults with type 2 diabetes, gout again occurred less often after starting an SGLT2 inhibitor than a GLP-1 drug, a difference of about 2.9 cases per 1,000 person-years.
• A network meta-analysis of 22 clinical trials found that SGLT2 inhibitors reduced gout risk, while GLP-1 drugs had only a neutral effect.

So the pattern is consistent across large datasets: SGLT2 drugs help gout, GLP-1 drugs mostly do not move the needle on their own. This does not mean a GLP-1 is useless for someone with gout. It means you should not pick one expecting it to treat the gout directly.

What this means if you have gout and take a GLP-1

Here is the practical read. A GLP-1 drug can still help your gout, but through the side door: losing weight lowers uric acid over time, and these drugs are very effective at weight loss. The drug is not treating your gout. The weight change is doing the work, slowly.

There is a catch worth knowing early. Rheumatology guidance notes that dehydration and very rapid weight loss can both trigger gout flares in the short term, even while the long-term trend is helpful. GLP-1 side effects like nausea, vomiting and diarrhea can leave you under-hydrated, which concentrates uric acid. So the first weeks on a GLP-1, when side effects peak, are exactly when a flare is more likely.

A few things protect you:

• Keep fluids up, especially if GI side effects hit. Steady hydration is one of the simplest ways to keep urate from spiking.
• Do not stop your urate-lowering medication. If you take allopurinol or febuxostat, a GLP-1 is not a replacement, and stopping can set off a flare.
• Go for steady weight loss rather than crash dieting, and tell your prescriber if flares increase.
• Protect your nutrition. The same appetite drop that drives weight loss shrinks how much you eat, and eating far less raises the risk of low protein, iron, vitamin B12 and other gaps. Closing those gaps is the exact problem GLP-1 Shield is built around.

On diet, the usual gout rules still apply and matter more during rapid weight change: go easy on high-purine foods like red meat, organ meat and shellfish, cut back on beer and spirits, and limit sugary drinks and fruit juice, which push uric acid up. If uric acid also shows up in your urine, that is a separate issue worth reading about in our piece on GLP-1 drugs and kidney stones.

For the wider picture of what these drugs do and do not do, our overview of GLP-1 side effects and our monitoring guide for vitamins on GLP-1 are good next stops.

Key takeaways

• GLP-1 drugs are not a gout or uric acid treatment, and their direct effect on urate is weak and inconsistent.
• Any gout benefit from a GLP-1 most likely comes from weight loss, not a direct drug effect.
• SGLT2 inhibitors have far stronger gout data; in large studies they lowered gout rates where GLP-1 drugs were neutral.
• Tirzepatide (Mounjaro, Zepbound) has no published gout data, and the only reliable GLP-1-type urate-lowerer, mazdutide, is still investigational.
• Dehydration and very fast weight loss can trigger flares early on, so keep fluids up and do not stop your prescribed gout medication.

Frequently asked questions

Does Ozempic lower uric acid?

Not reliably. In some small studies semaglutide, the drug in Ozempic, lowered serum urate, but in others it made no difference, and in one head-to-head trial it did not lower uric acid while an SGLT2 drug did. Any benefit seen is most likely from weight loss rather than a direct effect on uric acid.

Can Ozempic cause a gout flare?

It can, indirectly, especially early on. GLP-1 side effects like vomiting and diarrhea can cause dehydration, which concentrates uric acid, and very rapid weight loss can also trigger flares in the short term. Staying well hydrated and losing weight steadily lowers that risk. Tell your doctor if flares become more frequent.

Is a GLP-1 or an SGLT2 drug better for gout?

For gout and uric acid specifically, the evidence favours SGLT2 inhibitors such as empagliflozin and dapagliflozin. In large studies they lowered the rate of new gout, while GLP-1 drugs had a neutral effect. The right diabetes drug for you depends on your full health picture, so this is a conversation for your prescriber.

Should I stop my gout medication if I start Ozempic?

No. A GLP-1 drug is not a substitute for urate-lowering medication like allopurinol or febuxostat. Stopping those drugs can trigger a flare. Keep taking your prescribed gout medication unless your doctor tells you otherwise.